Posts

Novartis reportedly decides to pass on Cytokinetics

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Nonprofit health systems plug their strong cash ...

Nonprofit health systems plugged their strong cash reserves at JPM — a very diff...

STAT+: New congressional bill would thwart patent thick...

In the latest bid to lower the cost of medicines, a new bill was introduced in C...

STAT+: Fiery MedPAC meeting highlights massive overpaym...

Striking new data about Medicare Advantage overpayments led to an uncommon polit...

STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ s...

A preliminary FDA evaluation did not find evidence that GLP-1 drugs like Ozempic...

As she drives research on structural racism in health c...

As her research has gained prominence, health equity scholar Rachel Hardeman is ...

Opinion: The nursing staffing crisis has hit one role p...

The nursing staffing crisis has hit one role particularly hard: the nurse manager.

New York’s new doula plan will cover services for anyon...

More states are investing in the future of doula care. But relatively low reimbu...

STAT Virtual Event | 2024 JPM Recap, Live!

Get a full rundown of the deals, data, and scuttlebutt from #JPM24 from a crew o...

In partial reversal, Texas Medicaid greenlights first s...

“It opens the door, but at this point they’re giving only the bare minimum," sai...

The highs — and lows — of JPM 2024 you should pay atten...

In honor of JPM Week, you’re reading a special edition of our biotech newsletter...

Opinion: Pumping milk at JPM was a nightmare. It’s part...

Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry.

STAT+: Rune Labs, which makes an app to track Parkinson...

Rune Labs today announced it raised $12 million in funding led by Nexus NeuroTec...

GLP-1 drugs not linked to suicidal thoughts in FDA’s ea...

As use of drugs like Ozempic and Zepbound rises, agencies have yet to find causa...

Listen: Live! From JPM 2024

This week on "The Readout LOUD" podcast, live from #JPM24: A spate of deals and ...

Accolade beats analyst estimates, Teladoc’s optimism, a...

In the latest edition of STAT's health tech newsletter: Accolade jumps on positi...